Entrada Therapeutics (TRDA) EBIT: 2022-2025
Historic EBIT for Entrada Therapeutics (TRDA) over the last 4 years, with Sep 2025 value amounting to -$47.1 million.
- Entrada Therapeutics' EBIT fell 117.25% to -$47.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$121.6 million, marking a year-over-year decrease of 310.37%. This contributed to the annual value of $47.0 million for FY2024, which is 1586.75% up from last year.
- According to the latest figures from Q3 2025, Entrada Therapeutics' EBIT is -$47.1 million, which was down 0.43% from -$46.8 million recorded in Q2 2025.
- In the past 5 years, Entrada Therapeutics' EBIT registered a high of $53.4 million during Q2 2024, and its lowest value of -$47.1 million during Q3 2025.
- Over the past 3 years, Entrada Therapeutics' median EBIT value was -$5.9 million (recorded in 2024), while the average stood at -$6.5 million.
- Within the past 5 years, the most significant YoY rise in Entrada Therapeutics' EBIT was 465.28% (2024), while the steepest drop was 254.57% (2024).
- Entrada Therapeutics' EBIT (Quarterly) stood at -$25.6 million in 2022, then skyrocketed by 119.18% to $4.9 million in 2023, then slumped by 219.61% to -$5.9 million in 2024, then tumbled by 117.25% to -$47.1 million in 2025.
- Its EBIT stands at -$47.1 million for Q3 2025, versus -$46.8 million for Q2 2025 and -$21.8 million for Q1 2025.